AngioDynamics, Inc. (NASDAQ:ANGO) Shares Sold by Factorial Partners LLC

Factorial Partners LLC cut its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 3.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 113,000 shares of the medical instruments supplier’s stock after selling 3,500 shares during the quarter. Factorial Partners LLC owned 0.28% of AngioDynamics worth $1,035,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the company. US Bancorp DE increased its stake in shares of AngioDynamics by 1,938.0% during the 4th quarter. US Bancorp DE now owns 6,705 shares of the medical instruments supplier’s stock worth $61,000 after purchasing an additional 6,376 shares in the last quarter. Bank of New York Mellon Corp increased its position in AngioDynamics by 3.2% during the fourth quarter. Bank of New York Mellon Corp now owns 122,676 shares of the medical instruments supplier’s stock worth $1,124,000 after buying an additional 3,815 shares in the last quarter. Principal Financial Group Inc. acquired a new position in shares of AngioDynamics in the fourth quarter worth $879,000. Rhumbline Advisers raised its stake in AngioDynamics by 1.7% in the 4th quarter. Rhumbline Advisers now owns 60,479 shares of the medical instruments supplier’s stock valued at $554,000 after purchasing an additional 1,021 shares during the last quarter. Finally, White Pine Capital LLC lifted its stake in shares of AngioDynamics by 189.6% during the fourth quarter. White Pine Capital LLC now owns 64,033 shares of the medical instruments supplier’s stock valued at $587,000 after buying an additional 41,925 shares during the period. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Price Performance

Shares of ANGO opened at $9.29 on Friday. AngioDynamics, Inc. has a 12 month low of $5.26 and a 12 month high of $13.50. The stock has a market cap of $375.93 million, a PE ratio of -1.65 and a beta of 0.60. The stock’s 50-day moving average is $10.78 and its two-hundred day moving average is $8.51.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. The firm had revenue of $72.90 million during the quarter, compared to analysts’ expectations of $70.93 million. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. AngioDynamics’s quarterly revenue was down .1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.05) EPS. On average, research analysts anticipate that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

Insider Activity at AngioDynamics

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of the business’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total value of $49,978.60. Following the transaction, the senior vice president now owns 41,817 shares in the company, valued at $514,767.27. The trade was a 8.85 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 5.40% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright upped their price objective on shares of AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, January 10th.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.